Who are Metformin and Pioglitazone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Metformin / Pioglitazone Pill, Metformin, Pioglitazone, metformin and rosiglitazone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metformin-and-pioglitazone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Metformin and Pioglitazone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metformin and Pioglitazone (Metformin and Pioglitazone) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antidiabetic combination (biguanide + thiazolidinedione). Area: Diabetes.

marketed Antidiabetic combination (biguanide + thiazolidinedione) Metformin: AMP-activated protein kinase (AMPK) pathway; Pioglitazone: PPAR-gamma Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Metformin and Pioglitazone (Metformin and Pioglitazone) — King Edward Medical University. This combination reduces blood glucose by improving insulin sensitivity through two complementary pathways: metformin decreases hepatic glucose production and improves peripheral glucose uptake, while pioglitazone enhances insulin sensitivity in muscle and adipose tissue via PPAR-gamma activation.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Metformin and Pioglitazone TARGET	Metformin and Pioglitazone	King Edward Medical University	marketed	Antidiabetic combination (biguanide + thiazolidinedione)	Metformin: AMP-activated protein kinase (AMPK) pathway; Pioglitazone: PPAR-gamma
Metformin / Pioglitazone Pill	Metformin / Pioglitazone Pill	University of Catanzaro	marketed	Antidiabetic combination (biguanide + thiazolidinedione)	AMPK activation (metformin); PPAR-γ (pioglitazone)
Metformin, Pioglitazone	Metformin, Pioglitazone	Khyber Medical University Peshawar	marketed	Antidiabetic combination (biguanide + thiazolidinedione)	AMPK (metformin); PPARγ (pioglitazone)
metformin and rosiglitazone	metformin and rosiglitazone	New York Medical College	marketed	Antidiabetic combination (biguanide + thiazolidinedione)	AMPK (metformin); PPAR-γ (rosiglitazone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antidiabetic combination (biguanide + thiazolidinedione) class)

Khyber Medical University Peshawar · 1 drug in this class
King Edward Medical University · 1 drug in this class
New York Medical College · 1 drug in this class
University of Catanzaro · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Metformin and Pioglitazone — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-and-pioglitazone. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab